(Linda Ventresca, Chief Strategy Officer, AXIS Capital Holdings Limited. Image source: AXIS Capital.)
AXIS Capital Holdings Limited (Pembroke, Bermuda) has appointed Linda Ventresca to the newly created position of Chief Strategy Officer. Reporting directly to President and CEO Albert Benchimol, Ventresca will be responsible for guiding the development of the company’s strategic priorities and for managing the delivery of those priorities across the organization. She will continue to serve on the company’s Executive Committee.
Ventresca previously served as Chief Transformation Officer, and will continue to lead the company’s enterprise-wide transformation program, with the aim of capitalizing on changes reshaping the insurance marketplace, according to an AXIS statement. AXIS’ Corporate Development and Corporate Communications teams will continue to report to Ventresca.
“Linda is a respected leader, trusted advisor and the perfect person to serve as our first Chief Strategy Officer,” comments Benchimol. “She’s been with AXIS since nearly the beginning and has an expansive understanding of our business and the forces that our transforming the insurance industry. In addition to working with me to help shape our corporate strategy, Linda will serve as a partner to our Insurance and Reinsurance businesses and will help ensure there is direct alignment between our corporate strategies and the individual strategies that are being driven within our segments.”
Numerous Leadership Roles
Ventresca has spent more than 15 years at AXIS, during which time she has held numerous leadership roles within the organization, including Head of Corporate Development and Head of Investor Relations. Prior to joining AXIS, she was an investment associate at MMC Capital Inc., where she worked extensively with AXIS as a portfolio company of the Trident II fund. Previously, she had been a member of the Financial Institutions Investment Banking Groups at Donaldson, Lufkin & Jenrette, and UBS Securities LLC. Ms. Ventresca holds an M.B.A. from Columbia Business School and a B.S.E. in Bioengineering from the University of Pennsylvania.